GSE111247 temozolomide LN-308 14 v 7 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE111247_temozolomide_LN-308_14_v_7_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE111247_temozolomide_LN-308_14_v_7_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE111247_temozolomide_LN-308_14_v_7_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE111247_temozolomide_LN-308_14_v_7_human_up.

Results found

Linked to

 

Label

Description

 

Gene

SLC25A5 antisense RNA 1

Gene

uncharacterized LOC124904154

Gene

FAM167A antisense RNA 1

Gene

uncharacterized LOC124904048

Gene

KCNIP4 intronic transcript 1

Gene

long intergenic non-protein coding RNA 1498

Gene

DAP divergent transcript

Gene

SYNE1 antisense RNA 1

Gene

uncharacterized LOC105372266

Gene

patatin like domain 5, triacylglycerol lipase

  • Gene

    SLC25A5 antisense RNA 1


  • Gene

    uncharacterized LOC124904154


  • Gene

    FAM167A antisense RNA 1


  • Gene

    uncharacterized LOC124904048


  • Gene

    KCNIP4 intronic transcript 1


  • Gene

    long intergenic non-protein coding RNA 1498


  • Gene

    DAP divergent transcript


  • Gene

    SYNE1 antisense RNA 1


  • Gene

    uncharacterized LOC105372266


  • Gene

    patatin like domain 5, triacylglycerol lipase

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.